Payment overview · 2025
General Payments
$928.45
39 reported records · 12 companies
Healthcare provider profile · identity verified
Mohammed Najmuddin Karimjee, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HOUSTON, TX · NPI 1174188858
Verified facts
What the public records show
CMS Open Payments records show Mohammed Najmuddin Karimjee, MD received $928.45 in general payments during 2025 across 39 reported records.
ABBVIE INC. accounted for 36.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Linzess, Ozempic, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $342.96 | 36.9% | 19 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $143.55 | 15.5% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $120.91 | 13.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $116.28 | 12.5% | 5 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $38.24 | 4.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.86 | 3.5% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $26.87 | 2.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.27 | 2.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $22.40 | 2.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.67 | 2.3% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.17 | 2.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $18.27 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $928.45 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $147.08 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $143.55 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $123.64 | 7 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $120.91 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $116.28 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $75.47 | 4 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $64.87 | 4 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $38.24 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $38.24 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $32.86 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $26.87 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $25.27 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.40 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $21.67 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $7.37 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $7.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 30 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 39 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 38 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
39 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
30 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
38 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 257 | 140 |
| Tramadol Hcl | Tramadol Hcl | 182 | 55 |
| Amlodipine Besylate | Amlodipine Besylate | 178 | 103 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 169 | 95 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 161 | 55 |
| Gabapentin | Gabapentin | 156 | 81 |
| Levothyroxine Sodium | Levothyroxine Sodium | 132 | 66 |
| Alprazolam | Alprazolam | 126 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 110 | 63 |
| Lisinopril | Lisinopril | 108 | 62 |
| Metformin Hcl | Metformin Hcl | 103 | 61 |
| Mounjaro | Tirzepatide | 93 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 89 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 87 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 86 | 52 |
| Carvedilol | Carvedilol | 84 | 44 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 82 | 47 |
| Furosemide | Furosemide | 77 | 50 |
| Clonazepam | Clonazepam | 76 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 38 |
| Pregabalin | Pregabalin | 74 | 31 |
| Lorazepam | Lorazepam | 67 | 29 |
| Losartan Potassium | Losartan Potassium | 67 | 43 |
| Omeprazole | Omeprazole | 64 | 36 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 59 | 31 |
| Famotidine | Famotidine | 58 | 30 |
| Meloxicam | Meloxicam | 58 | 29 |
| Celecoxib | Celecoxib | 55 | 28 |
| Montelukast Sodium | Montelukast Sodium | 55 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 54 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 54 | 29 |
| Pioglitazone Hcl | Pioglitazone Hcl | 51 | 26 |
| Farxiga | Dapagliflozin Propanediol | 48 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 45 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 23 |
| Trazodone Hcl | Trazodone Hcl | 45 | 24 |
| Buspirone Hcl | Buspirone Hcl | 43 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 21 |
| Ezetimibe | Ezetimibe | 41 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 41 | 24 |
| Temazepam | Temazepam | 41 | 21 |
| Glimepiride | Glimepiride | 40 | 24 |
| Linzess | Linaclotide | 39 | 15 |
| Metformin Hcl Er | Metformin Hcl | 39 | 16 |
| Donepezil Hcl | Donepezil Hcl | 38 | 24 |
| Ozempic | Semaglutide | 38 | 21 |
| Irbesartan | Irbesartan | 37 | 19 |
| Simvastatin | Simvastatin | 37 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | 22 |
| Alendronate Sodium | Alendronate Sodium | 34 | 18 |
| Prednisone | Prednisone | 33 | 29 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | 18 |
| Jardiance | Empagliflozin | 30 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 29 | 20 |
| Eliquis | Apixaban | 29 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | 20 |
| Methylprednisolone | Methylprednisolone | 29 | 29 |
| Spironolactone | Spironolactone | 29 | suppressed |
| Mirtazapine | Mirtazapine | 28 | 12 |
| Nifedipine Er | Nifedipine | 28 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 22 |
| Azithromycin | Azithromycin | 27 | 27 |
| Sertraline Hcl | Sertraline Hcl | 27 | 16 |
| Glipizide | Glipizide | 26 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | 16 |
| Bupropion Xl | Bupropion Hcl | 25 | 14 |
| Allopurinol | Allopurinol | 24 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 22 | 16 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Cefdinir | Cefdinir | 21 | 19 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | 11 |
| Diazepam | Diazepam | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 17 |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Baclofen | Baclofen | 16 | 12 |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 14 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 12 |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 14 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $928.45 · 39 records | ABBVIE INC. | Auvelity, CAPLYTA, CREON, JARDIANCE, KRYSTEXXA, Kerendia, LINZESS, Natroba, Ozempic, QULIPTA, SYNTHROID, Spinosad, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Veozah | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error